反应详情

A solution of benzyloxyacetyl chloride (142 mg, 767 μmol) in DCM (2 mL) is added to a solution of 2-chloro-4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenylamine (30 mg, 77 μmol) in DCM (2 mL). The mixture is stirred at rt for 15 h. The mixture is diluted with diethyl ether and washed with 1 N aq. HCl. The organic extract is washed with 33% aq. KOH solution, dried over MgSO4, filtered and concentrated. The crude product is purified by reverse phase MPLC to give 2-benzyloxy-N-{2-chloro-4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenyl}-acetamide (12 mg) as a pale yellow oil; LC-MS: tR=0.68 min; [M+1]+=529.18. The material is dissolved in THF:ethanol 1:1 (5 mL) and Pd/C (10 mg, 10% Pd) is added. The mixture is stirred at rt for 15 h under 5 bar of H2. The catalyst is removed by filtration and the filtrate is concentrated. The crude product is purified on prep. TLC plates with DCM containing 4% of methanol to give the title compound (4 mg) as a white solid; LC-MS: tR=0.50 min; [M+1]+=448.98; 1H NMR (CD3OD): δ 1.13 (t, J=7.0 Hz, 6H), 2.29 (s, 3H), 2.39 (s, 3H), 2.66 (q, J=6.8 Hz, 4H), 3.80 (s, 2H), 4.24 (s, 2H), 7.75 (s, 1H), 8.00 (s, 1H), 8.06 (s, 1H).

1. washwashed with 1 N aq. HCl
2. extractionThe organic extract
3. washis washed with 33% aq. KOH solution
4. dry with materialdried over MgSO4
5. filtrationfiltered
6. concentrationconcentrated
7. customThe crude product is purified by reverse phase MPLC